Trials / Completed
CompletedNCT06733298
A Study Investigating [14C]-Labeled RO7269162 in Healthy Male Participants
Open-Label, Non-Randomized Study Investigating the Excretion Balance, Pharmacokinetics, and Metabolism of a Single Oral Dose of [14C]-Labeled RO7269162 in Healthy Male Participants
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 8 (actual)
- Sponsor
- Hoffmann-La Roche · Industry
- Sex
- Male
- Age
- 35 Years – 64 Years
- Healthy volunteers
- Accepted
Summary
This study will investigate how RO7269162 labeled with a carbon tracer (\[14C\]) is absorbed, metabolized, and eliminated by the body after a single dose in healthy male volunteers.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | [ 14C]-labeled RO7269162 | Participants will receive one oral dose of \[14C\]-labeled RO7269162. |
Timeline
- Start date
- 2025-01-08
- Primary completion
- 2025-01-29
- Completion
- 2025-01-29
- First posted
- 2024-12-13
- Last updated
- 2025-02-25
Locations
1 site across 1 country: Netherlands
Source: ClinicalTrials.gov record NCT06733298. Inclusion in this directory is not an endorsement.